发明名称 |
Composition |
摘要 |
Pharmaceutical compositions and methods for the treatment of neoplastic disease and comprising the combination of a taxane, such as docetaxel, with a CYP3A4 inhibitor, such as ritonavir. Methods of treatment of neoplastic disease incorporating the administration of a taxane and the administration of a CYP3A4 inhibitor, either simultaneously or separately, are also included. Further, kits for carrying out the methods are included. Solid pharmaceutical taxane compositions for oral administration comprising a substantially amorphous taxane, a carrier and a surfactant are also included. |
申请公布号 |
US9089544(B2) |
申请公布日期 |
2015.07.28 |
申请号 |
US200812197432 |
申请日期 |
2008.08.25 |
申请人 |
Slotervaart Participaties BV;Stichting Het Nederlands Kanker Instituut |
发明人 |
Beijnen Jacob Hendrik;Schellens Johannes Henricus Matthias;Moes Johannes Jan;Nuijen Bastiaan |
分类号 |
A61K9/14;A61K31/337;A61K9/16;A61K9/48;A61K31/427;A61K9/00 |
主分类号 |
A61K9/14 |
代理机构 |
Banner & Witcoff, Ltd. |
代理人 |
Banner & Witcoff, Ltd. |
主权项 |
1. A solid pharmaceutical composition for oral administration comprising a substantially amorphous taxane, a hydrophilic carrier, and a surfactant, wherein the taxane is partly molecularly dispersed in the hydrophilic carrier, wherein the hydrophilic carrier is PVP-K30, wherein the surfactant is sodium dodecyl sulphate, wherein the taxane to hydrophilic carrier weight ratio is about 1:9 w/w, and wherein the weight ratio of surfactant to taxane is about 1:1 w/w. |
地址 |
Amsterdam NL |